Aardvark Therapeutics, Inc. Common Stock
$7.60+52.0%YTD-42.9%1Y-39.7%
Mentions · last 7 days
117
Price updated 13h ago·X counts updated 13h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $AARD.
Biotechnology
IBB +2.9% on GLP-1 pipeline momentum and MRNA's post-9-0 FDA vote continuation — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
Top industry ETF
$IBBiShares Biotechnology ETF
+13.2%YTD
+43.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-2.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-85.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-37.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-61.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.99$-0.87-14.0%
Q4 2025Mar 23, 2026$-0.81$-0.83+2.1%
Q3 2025Nov 13, 2025$-0.75$-0.80+6.1%
Q2 2025Aug 13, 2025$-0.66$-0.60-10.0%
Next earningsWed, Aug 12·consensus EPS $-0.86
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.99$-18.9M
Q4 FY25$0———$-0.81$-14.4M
Q3 FY25$0———$-0.75$-18.5M
Q2 FY25$0———$-0.66$-9.9M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$300K$300K – $300K-$3.59-$4.56 – -$2.2810
FY27$1.0M$1.0M – $1.0M-$3.26-$4.27 – -$1.716
FY28$6.6M$6.6M – $6.6M-$2.93-$5.28 – -$1.447
FY29$89.0M$89.0M – $89.0M-$1.64-$1.64 – -$1.643
FY30$277.7M$277.7M – $277.7M$0.62$0.62 – $0.626
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.18.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.29%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+58.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-17.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 10.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today36.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.935-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change
AI summary
8-KMaterial agreementMar 248-K — Item 1.01: Material agreement
8-KOfficer or director changeFeb 128-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 15 other (4 routine 8-Ks · 2 earnings 8-Ks · 1 ARS · 1 proxy) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
In themes
Explore the broader themes this ticker is being talked about under.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $AARD on X in the last 7 days.